← Back to Search

PD-1 Inhibitor

TATE + Pembrolizumab for Lung Cancer

Verified Trial
Phase 2
Recruiting
Research Sponsored by Teclison Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have you been diagnosed with non-small cell lung cancer?
Has your lung cancer spread to your liver?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing a new cancer treatment involving Trans-arterial Tirapazamine Embolization (a minimally-invasive procedure) and Pembrolizumab (a cancer immunotherapy drug). The trial is for patients with metastatic non-small cell lung cancer that has spread to the liver, and who have not responded to other treatments.

Who is the study for?
This trial is for adults with metastatic non-small cell lung cancer (NSCLC) who have already tried PD-1/PD-L1 inhibitors and chemotherapy. Patients whose disease has worsened after treatment are eligible to participate.Check my eligibility
What is being tested?
The study tests whether combining Tirapazamine with embolization could enhance anti-tumor immunity and make Pembrolizumab effective in lung cancer patients who have failed prior immunotherapy.See study design
What are the potential side effects?
Possible side effects include immune-related reactions due to Pembrolizumab like rash or colitis, liver issues from TATE, fatigue, skin changes, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate (ORR)
Secondary outcome measures
Duration of Response
PFS
Response rate
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NSCLCExperimental Treatment1 Intervention
Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy

Find a Location

Who is running the clinical trial?

Teclison Ltd.Lead Sponsor
3 Previous Clinical Trials
213 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,868 Previous Clinical Trials
5,051,878 Total Patients Enrolled
Ray LeeStudy DirectorTeclison Limited

Media Library

Pembrolizumab (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04701476 — Phase 2
Lung Cancer Research Study Groups: NSCLC
Lung Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT04701476 — Phase 2
Pembrolizumab (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04701476 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the overarching objective of this experiment?

"For the next two years, this medical trial will be monitoring primary outcome of Overall Response Rate (ORR) among patients with NSCLC. Additionally, they are tracking secondary outcomes such as Overall Survival (OS), Progression Free Survival (PFS), and Duration of Response according to RECIST 1.1 guidelines."

Verified Answer

How many individuals are selected for participation in this research project?

"Affirmative. The information hosted on clinicaltrials.gov reveals that this experiment, which was initially made public on May 20th 2021, is presently seeking participants. A total of 110 volunteers are required to be recruited from a single medical facility."

Verified Answer

What other scientific investigations have been conducted to explore the effects of TATE and pembrolizumab?

"At present, 961 clinical studies are running examining the effectiveness of TATE and pembrolizumab. Of those trials, 122 have advanced to Phase 3. The bulk of these experiments take place in Houston, Texas; however there are 35731 different medical sites running tests with this treatment worldwide."

Verified Answer

To what conditions have TATE and pembrolizumab been effectively deployed?

"TATE and pembrolizumab is a therapeutic intervention frequently used to combat malignant neoplasms, although it can also be employed in cases of unresectable melanoma, microsatellite instability high, or post-chemotherapy disease progression."

Verified Answer

Is the process of enrolling in this trial open at present?

"Correct. Clinicaltrials.gov contains data that confirms the recruitment period of this clinical trial, which began on May 20th 2021 and was last updated April 13th 2022 is still active. One location is needed to meet the goal of enrolling 110 patients in total."

Verified Answer

Is the concurrent use of TATE and pembrolizumab considered to be a safe therapeutic approach?

"Our internal assessment gauged the safety of TATE and pembrolizumab as a 2, due to Phase 2 trial results that demonstrate some security but no evidence for efficacy."

Verified Answer

Who else is applying?

What site did they apply to?
UC Irvine Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria

Why did patients apply to this trial?

To help save my life.
PatientReceived 1 prior treatment
~39 spots leftby Oct 2025